-
induce posterior vitreous detachment in
vitreomacular adhesion patients.
ThromboGenics, the
manufacturer of ocriplasmin,
encountered several problems when...
-
Oncology Tara
Innovations Terumo Medical 3D
Biotek The
Medicines Company ThromboGenics TKL
Research Tris
Pharma Validus Pharmaceuticals VaxInnate West-Ward...
-
traumatic to the vitreous, and is
potentially prophylactic. As of 2012,
ThromboGenics is
still developing the
ocriplasmin biological agent.
Ocriplasmin is...
-
public utility (SON). He also
founded the
companies "Thromb-X NV", "
ThromboGenics NV" (now “Oxurion NV“) and the
investment fund "Fundplus NV”. In 2020...
-
Tessenderlo Chemistry TESB
March 1991 –
January 1993 July 1998 –
March 2004
ThromboGenics Biopharmaceuticals THR
March 2013 –
March 2014
Tractebel Energy No longer...
-
affiliated (as spin-offs) with the
university and its research. IMEC,
Thrombogenics - now
Oxurion and
Materialise NV are some of the most important. The...
- and
other stimuli (such as hypercholesterolemia) can lead to
changes in
gene expression in
endothelium producing to a pro-thrombotic state. When this...
-
showed that some
mutations of CYP2C19, CYP3A4, CYP2C9, CYP2B6, and CYP1A2
genes could affect the
clinical efficacy and
safety of
clopidogrel treatment....
- (March 2019). "Behçet's
syndrome as a tool to
dissect the
mechanisms of
thrombo-inflammation:
clinical and
pathogenetic aspects".
Clinical and Experimental...
- platelet-leukocyte
aggregates are
increased in
acute and
chronic sterile thrombo-inflammatory diseases.
Plasma calprotectin is
elevated in
persons with...
